NMN Shows Promise for Treating Severe Pancreatitis Linked to High Triglycerides

Acute pancreatitis becomes particularly dangerous when triggered by high triglyceride levels (hypertriglyceridemia), as elevated blood fats worsen inflammation and impair the pancreas's ability to heal. This condition affects thousands annually and can be life-threatening without effective treatment options.

Researchers tested whether nicotinamide mononucleotide (NMN), a supplement that boosts cellular NAD+ levels, could protect against this severe form of pancreatitis. They used both laboratory cell cultures and mouse models to examine NMN's effects on pancreatic damage and repair processes.

The results were promising across multiple measures. NMN protected pancreatic acinar cells from damage caused by oleic and palmitic acids (fatty acids that accumulate in hypertriglyceridemia). In mice with induced pancreatitis, repeated NMN treatment significantly reduced pancreatic injury, lowered inflammatory markers, decreased blood lipid levels, and reduced harmful reactive oxygen species.

Mechanistically, NMN worked by increasing NAD+ levels, which activated SIRT1 proteins that suppressed TXNIP (a protein that promotes cellular stress). Additionally, NMN influenced immune cell behavior by inhibiting NOTCH signaling pathways, promoting beneficial M2-type macrophages that accelerate tissue repair rather than perpetuate inflammation.

These findings suggest NMN could provide a novel therapeutic strategy for hypertriglyceridemia-associated pancreatitis. However, the research was conducted in laboratory settings and animal models, so human clinical trials would be needed to confirm safety and effectiveness in patients with this serious condition.